ClinicalTrials.gg
CompletedNCT03208218Updated Jul 6, 2017

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

A Phase 1 interventional study of SYP-1512 and Revlimid cap in Healthy, Male, sponsored by Samyang Biopharmaceuticals Corporation. Completed. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-06.

Sponsored by Samyang Biopharmaceuticals Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Aug 2016, registered Jun 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg) when administered a single-dose to healthy male volunteers.

Read the detailed description

Healthy volunteers are administrated single-dose over the period I and II (crossover) of SYP-1512 Tab and Revlimid cap (25mg) as of lenalidomide 25mg.

Every time before and after each medication, pharmacokinetic (PK) parameters and safety of SYP-1512 Tab and Revlimid cap (25mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively

02

Conditions studied

  • Healthy, Male

Keywords

  • Evaluation of the pharmacokinetics equivalence
  • Healthy volunteers
  • Single dose over the period I and II(crossover)
  • Healthy male volunteers
03

In context

Lead sponsor

Samyang Biopharmaceuticals Corporation is the lead sponsor of 30 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Over 20aged in healthy males
  2. Those who do not have congenital or chronic diseases or pathological symptoms based on screening.
  3. The person who is determined to be the subject of the clinical laboratory test results such as hematology test, blood chemistry test, urine test, etc. set by the person in charge of the examination of the medical institution
  4. : 18-30
  5. Those who have not donated blood within 2 weeks
  6. Those without a history of gastrointestinal resection
  7. Those who have no history of mental illness within the last 5 years
  8. Agreement with written
  9. Anyone who can follow and follow all scheduled admission and outpatient visits, dosing, clinical laboratory testing and subject compliance
  10. If the partner is a woman of childbearing age who does not use the appropriate method of (even if the man has undergone a vasectomy), while taking lenalidomide, during the interruption, for consenting to use condoms for 28 days after the last dose
  11. In the vital sign measured in a sitting position, the systolic blood pressure ≤145 mmHg and ≥100 mmHg, the diastolic blood pressure ≤95 mmHg and ≥60 mmHg, the pulse rate> 40 and \<100 times / minute
  12. (ECG) of the 12-electrode, ≤ 450 msec
  13. Those who have agreed not to donate blood or plasma and semen for at least 28 days after taking this drug
  14. If the contraceptive is withdrawn due to contraception or partner's pregnancy confirmation during testing. Those who agree to respond to follow-up within 6 months after pregnancy and after delivery

Exclusion criteria

Exclusion Criteria:

  1. Those taking drugs that significantly induce drug metabolizing enzymes within one month before screening (eg, barbiturate) or inhibit
  2. Those taking medication that could affect the test within 10 days before screening
  3. The person who is in charge of the examination of the medical institution (or the examining doctor who is delegated)
  4. Those who have participated in the bioequivalence test or other clinical studies within 3 months prior to the administration of the test and administered the clinical trial drug
  5. Persons with to venous puncture
  6. Screening Within the first 6 months, a person with a history of regular alcohol consumption as follows: 1 cup = 150 mL of wine or 360 mL of beer or 45 mL of distillate)
  7. Patients with severe hepatic impairment
  8. Patients who are hypersensitive to NSAIDs and other components of NSAID
  9. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  10. Patients with renal impairment (-type creatinine clearance \<50 mL / min)
  11. Positive result of Serum test [RPR Ab (VDRL), , Ab, anti (AIDS)]
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    SYP-1512

    Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

    Drug: SYP-1512

  • Active comparator
    Revlimid cap.

    Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)

    Drug: Revlimid cap

Interventions

  • Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)

    Also known as: Lenalidomide 25mg

  • Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I\&II D1(crossover)

    Also known as: Lenalidomide 25mg

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of the AUCt between SYP-1512 and Revlimid cap(25mg)

    Bioequivalance of the AUCt between SYP-1512 and Revlimid cap(25mg)

    Time frame: 0-24hours

  2. Pharmacokinetics of the Cmax between SYP-1512 and Revlimid cap(25mg)

    Bioequivalance of the Cmax between SYP-1512 and Revlimid cap(25mg)

    Time frame: 0-24hours

Secondary outcomes

  1. Pharmacokinetics of the AUCinf SYP-1512 and Revlimid cap (25mg)

    Bioequivalance of the AUCinf SYP-1512 and Revlimid cap (25mg)

    Time frame: 0-inf

  2. Pharmacokinetics of the Tmax of SYP-1512 and Revlimid cap (25mg)

    Bioequivalance of the Tmax of SYP-1512 and Revlimid cap (25mg)

    Time frame: 0-24hours

  3. Pharmacokinetics of the T1/2 of SYP-1512 and Revlimid cap (25mg)

    Bioequivalance of the T1/2 of SYP-1512 and Revlimid cap (25mg)

    Time frame: 0-24hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Aug 2016, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2017
First posted
Jul 5, 2017
StartActual
Aug 17, 2016
Primary completionActual
Aug 25, 2016
CompletionActual
Oct 31, 2016
Last update
Jul 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03208218
Collaborators
Chungnam National University Hospital
Responsible party
Sponsor
First posted
Jul 5, 2017
Start date
Aug 17, 2016
Primary completion
Aug 25, 2016
Completion
Oct 31, 2016
Last update
Jul 6, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion